Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa

Blood

Volumn 100, Issue 6, 2002, Pages 2071-2076

  Bougie, Daniel W ^a,b,c,d   Wilker, Peter R ^a,b,c,d   Wuitschick, Elizabeth D ^a,b,c,d   Curtis, Brian R ^a,b,c,d   Malik, Mohammad ^a,b,c,d   Levine, Stewart ^a,b,c,d   Lind, Richard N ^a,b,c,d   Pereira, Jaime ^a,b,c,d   Aster, Richard H ^a,b,c,d  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; TIROFIBAN;

ADULT; AGED; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BINDING SITE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG BINDING; FEMALE; HUMAN; HUMAN CELL; MALE; MOLECULAR RECOGNITION; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 0037105428     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v100.6.2071.h81802002071_2071_2076     Document Type: Article

References (44)

1. Perspectives series: Cell adhesion in vascular biology. Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics
2. Platelet GPIIb-IIIa blockers
3. Oral platelet glycoprotein IIb/IIIa inhibitors
4. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
5. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
6. Inhibition of the platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation
7. In vitro and in vivo studies on the metabolism of tirofiban
8. Clinical pharmacology of eptifibatide
9. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study
10. Primary and secondary safety endpoints from IMPACT II
11. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
12. Antibodies associated with sulfon-amide-induced immune thrombocytopenia react preferentially with calcium-dependent epitopes on the glycoprotein IIb/IIIa complex
13. Detection of drug-dependent, platelet-reactive antibodies by antigen capture ELISA and flow cytometry
14. A recombinant, soluble form of the integrin GPIIb/IIIa spontaneously assumes an active, ligand binding conformation and is recognized by GPIIb/IIIa-specific monoclonal, allo-, auto-, and drug-dependent antibodies
15. Synergistic action of two murine monoclonal antibodies that inhibit ADP-induced platelet aggregation without blocking fibrinogen binding
16. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects
17. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells
18. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment
19. Orbofiban: An orally active GPIIb/IIIa platelet receptor antagonist
20. 2+-dependent binding of a synthetic Arg-Gly-Asp (RGD) peptide to a single site on the purified platelet glycoprotein IIb/IIIa complex
21. 2+ binding site on the β3-integrins that regulates the dissociation rate for RGD ligands
22. Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: Distinct binding profile for roxifiban
23. Dissecting the epitope for the 7E3 mAb by generating human/mouse chimeric C177-C184 disulfide-loops in the human β3 integrin
24. 3
25. Interaction of AP-2 a monoclonal antibody specific for human platelet glycoprotein IIb/IIIa complex, with intact platelets
26. Effect of calcium on the stability of the platelet membrane glycoprotein IIb-IIIa complex
27. Divalent cation regulation of the surface orientation of platelet membrane glycoprotein IIb
28. Topography of ligand-induced binding sites, including a novel cation-sensitive epitope (AP5) at the amino terminus, of the human integrin β3 subunit
29. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
30. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome: The platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrelin therapy (PURSUIT) trial experience
31. Acute thrombocytopenia after treatment with the oral fibrinogen receptor antagonist xemilofiban: Clinical presentation and evidence for an immune etiology
32. Drug-antibody-platelet interaction in quinine- and quinidine-induced thrombocytopenia
33. Localization of an Arg-Gly-Asp recognition site within an integrin adhesion receptor
34. IIb
35. 2+-dependent structural transitions of the platelet glycoprotein IIb-IIIa complex: Preparation of stable glycoprotein IIb and IIIa monomers
36. 3-integrins
37. Are changes In integrin affinity and conformation overemphasized?
38. Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion
39. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor
40. 3
41. Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists
42. 3-mediated intracellular Ca2+ signaling
43. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and Rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa
44. Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist Roxifiban: Implications for the etiology of thrombocytopenia